EuroIntervention PCRonline - Connecting with the community

Just accepted article

Polymer-Free Drug-Coated Coronary Stents Are Cost-Effective in Patients at High Bleeding Risk: Economic Evaluation of the LEADERS FREE Trial

Disclaimer:

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers. To read the full content of this article, please download the PDF.

Sign in to download the full article

1. Assistance Publique - Hopitaux de Paris, URC-Eco, Paris, FRANCE; 2. Assistance Publique Hopitaux de Paris, URCEco & Santé publique, Hôpital Henri Mondor ; Université Paris Est Créteil, INSERM ECEVE UMR 1123 PARIS, France; 3. Assistance Publique Hopitaux de Paris, URCEco & Santé publique, Hôpital Henri Mondor; 4. Biosensors, Morges, SWITZERLAND;; 5. Hôpital Privé Jacques Cartier 6 avenue du Noyer Lambert, Massy, FRANCE;; 6. Hospital Alvaro Cunqueiro (Complejo Hospitalario Universitario de Vigo), Vigo, SPAIN; 7. Azienda Ospedaliera San Camillo Forlanini, Rome, ITALY; 8. Golden Jubilee National Hospital West of Scotland Regional Heart & Lung Centre, Glasgow, UNITED KINGDOM; 9. Royal Bournemouth Hospital Dorset Heart Centre, Bournemouth, UNITED KINGDOM; 10. Segeberger Kliniken GmbH Herzzentrum, Bad Segeberger, GERMANY; 11. CERC, Massy, FRANCE; 12. Hopital de la Tour, 1217, Geneva, SWITZERLAND; 13. Hôpital Privé Jacques Cartier 6 avenue du Noyer Lambert, Massy, FRANCE

Abstract

Aims: In patients at high risk of bleeding who undergo PCI the biolimus A9 polymer-free drug coated stent (DCS) has superior efficacy and safety compared to a bare metal stent (BMS). We estimated the cost effectiveness of DCS vs. BMS.

Methods and results: The Leaders FREE-bas…

– OR –